News & Events
The information in our press releases should be considered accurate only as of the date of the press release. We disclaim any obligation to supplement or update the information in these press releases.
Trudhesa is the First and Only Therapeutic to Use POD® Technology to Deliver Dihydroergotamine Mesylate (DHE)—a Proven, Well-Established Therapeutic—to the Vascular-Rich Upper Nasal Space Trudhesa is Available Through Trudhesa Direct™, Which Will Provide Hassle-Free Prescribing, Savings and Home Delivery Facilitated…
READ MORE
SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) — Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced…
READ MORE
SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) — Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that…
READ MORE
TRUDHESA Is the First and Only Therapeutic to Use POD technology to Deliver Dihydroergotamine Mesylate (DHE) to the Vascular-Rich Upper Nasal Space TRUDHESA Is Well Tolerated and Delivers Rapid, Sustained and Consistent Symptom Relief for the Acute Treatment of Migraine…
READ MORE
TRUDHESA™ New Drug Application (NDA) Under Review by U.S. Food & Drug Administration (FDA) with PDUFA Target Action Date of September 6, 2021 Preparations On Track for Potential TRUDHESA Launch in the Fourth Quarter of 2021 Increased Cash Position and Extended…
READ MORE
SEATTLE, August 9, 2021 — Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced it…
READ MORE
Study Shows TRUDHESA™ Was Well Tolerated and Delivered Rapid, Consistent Symptom Relief Exploratory Patient-Reported Outcomes Data Indicated More Than One Third of Patients Experienced Pain Freedom and Two Thirds Had Pain Relief Two Hours Following TRUDHESA™ Administration Among the 38…
READ MORE
SEATTLE, Aug 3, 2021 – Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that…
READ MORE
SEATTLE, July 29, 2021 (GLOBE NEWSWIRE) — Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today…
READ MORE
Data Will Evaluate Exploratory Efficacy Data from STOP-301 Study Evaluating INP104 Consistency of Response, Recurrence and Sustained Response Findings Also Highlight Safety and Tolerability Including Nausea and Nasal and Cardiovascular Safety as a Promising Potential New Option for the Treatment…
READ MORE
